RenovoRx has developed the RenovoCath™, which is FDA cleared and now being investigated in an active clinical trial to prove extended median survival and improved quality of life.
The RenovoCath is specifically designed for targeted delivery of fluids, including diagnostic and therapeutic agents, into selected sites in the peripheral vascular system. The proximal and distal occlusion balloons enable isolation of the vascular site while allowing infusion of fluids in a controlled environment – where they’re most effective.
The RenovoCath provides a unique approach, using Trans-Arterial Micro-Perfusion™ (TAMP™) to target delivery of an agent directly to the disease site. The RenovoCath TAMP delivery method is being investigated in the TIGeR-PaC clinical study, enrolling newly-diagnosed, locally-advanced pancreatic cancer patients.
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
The RenovoRx RC 120 is cleared for chemotherapeutic drug infusion to selected sites in the peripheral vascular system. Prior to use, please refer to the RenovoRx RC 120 IFU for complete product indications, warnings, precautions, contraindications, potential adverse effects and detailed instructions for use.